Vaccine

Bitscopic appoints Kelly Echevarria, Pharm.D., BCIDP to advance VA antimicrobial stewardship with PraediAlert

After 25+ years in VA infectious diseases and national leadership, Echevarria joins Bitscopic to help VAMCs strengthen antimicrobial stewardship programs (ASP)…

4 weeks ago

Ascend Unveils Proprietary Enhancers That Significantly Improve AAV Yields Without Compromising Quality

New data from Ascend's R&D team demonstrate up to 3-fold increase in AAV yields, supporting greater efficiency and scalability across…

4 weeks ago

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

New biomarker and immune data presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual MeetingFollowing the recent presentation…

1 month ago

E&I Cooperative Services Awards Cenmed Enterprises Contract for Medical, Laboratory, and Sports Medicine Products

NEW BRUNSWICK, NEW JERSEY / ACCESS Newswire / November 6, 2025 / E&I Cooperative Services (E&I), the only member-owned, nonprofit…

1 month ago

Encouraging Results from a First-in-Human Phase 1 Clinical Trial of IAVI’s Lassa Vaccine Candidate Published in New England Journal of Medicine

One dose elicits robust and long-lasting immune responses in healthy adults in the U.S. and LiberiaKey takeaways:IAVI's Lassa vaccine candidate…

1 month ago

Encouraging Results from a First-in-Human Phase 1 Clinical Trial of IAVI’s Lassa Vaccine Candidate Published in New England Journal of Medicine

One dose elicits robust and long-lasting immune responses in healthy adults in the U.S. and LiberiaKey takeaways:IAVI's Lassa vaccine candidate…

1 month ago

Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51)Narrows 2025 projected…

1 month ago

Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51)Narrows 2025 projected…

1 month ago

IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025

LAWRENCEVILLE, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with…

1 month ago